激酶抑制剂OTSSP167在T细胞急性淋巴细胞白血病中的抗白血病作用
研究显示OTSSP167对T-ALL细胞系有纳摩尔级细胞毒性(IC50 10-50 nM),可诱导凋亡和细胞周期阻滞,部分与抑制MAP2K7激酶活性及降低JNK活化相关,并抑制mTOR和NOTCH1通路;10 mg/kg每日腹腔给药在小鼠中耐受良好且无血液学毒性,可减少细胞系异种移植模型中的人T-ALL细胞扩增,并在3例患者来源异种移植中控制血液、骨髓和脾脏的白血病负荷、延长生存;与地塞米松、左旋门冬酰胺酶、长春新碱和依托泊苷联用呈协同作用。
要点
- OTSSP167对T-ALL细胞系IC50为10-50 nM,诱导凋亡和细胞周期阻滞
- 10 mg/kg每日腹腔给药小鼠耐受良好、无血液学毒性,可减少T-ALL细胞扩增
- 与地塞米松、左旋门冬酰胺酶、长春新碱和依托泊苷联用呈协同作用
核心结论
- OTSSP167在T-ALL中具有抗白血病作用,支持其作为辅助药物用于提高儿童T-ALL治疗反应并减少复发。
研究设计与样本
- 体外T-ALL细胞系研究及细胞系异种移植模型和3例患者来源异种移植的小鼠体内研究。
主要发现
- OTSSP167对一组T-ALL细胞系呈剂量依赖性细胞毒性,IC50在纳摩尔范围(10-50 nM)。
- OTSSP167诱导T-ALL细胞系凋亡和细胞周期阻滞,至少部分与抑制MAP2K7激酶活性及降低其下游底物JNK活化相关。
- OTSSP167还抑制mTOR和NOTCH1等其他白血病T细胞生存通路。
- 每日腹腔注射10 mg/kg OTSSP167耐受良好,小鼠无血液学毒性,并有效减少细胞系异种移植模型中的人T-ALL细胞扩增。
- 相同剂量OTSSP167有效控制3例患者来源异种移植的血液、骨髓和脾脏白血病负荷,并延长生存。
关键数值与推荐
- OTSSP167对T-ALL细胞系的IC50为10-50 nM。
- 小鼠每日腹腔注射OTSSP167 10 mg/kg。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Novel drugs are needed to increase treatment response in children with high-risk T-cell acute lymphoblastic leukemia (T-ALL). Following up on our previous report on the activation of the MAP2K7-JNK pathway in pediatric T-ALL, here we demonstrate that OTSSP167, recently shown to inhibit MAP2K7, has antileukemic capacity in T-ALL. OTSSP167 exhibited dose-dependent cytotoxicity against a panel of T-ALL cell lines with IC50 in the nanomolar range (10-50 nM). OTSSP167 induces apoptosis and cell cycle arrest in T-ALL cell lines, associated at least partially with the inhibition of MAP2K7 kinase activity and lower activation of its downstream substrate, JNK. Other leukemic T-cell survival pathways, such as mTOR and NOTCH1 were also inhibited. Daily intraperitoneal administration of 10 mg/kg OTSSP167 was well tolerated, with mice showing no hematological toxicity, and effective at reducing the expansion of human T-ALL cells in a cell-based xenograft model. The same dosage of OTSSP167 efficiently controlled the leukemia burden in the blood, bone marrow, and spleen of 3 patient-derived xenografts, which resulted in prolonged survival. OTSSP167 exhibited synergistic interactions when combined with dexamethasone, L-asparaginase, vincristine, and etoposide. Our findings reveal novel antileukemic properties of OTSSP167 in T-ALL and support the use of OTSSP167 as an adjuvant drug to increase treatment response and reduce relapses in pediatric T-ALL.
引用
- Bridges CS, Chen TJ, Puppi M, et al. Antileukemic properties of the kinase inhibitor OTSSP167 in T-cell acute lymphoblastic leukemia. Blood Adv. 2023. PMID: 36399528. doi:10.1182/bloodadvances.2022008548
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。